Code
MOG-JAQX-01BX
Test
Active-Compendium
81270 (x1)
Clinical
Oncology,Pathology
<p><b>Bone Marrow Aspirate:</b> 2 mL in EDTA tube.<br>
<b>Peripheral Blood:</b> 5 mL in EDTA tube.<br>
<b>Note:</b> Test is DNA-based. Please select Extract & Hold - DNA if specimen hold service is desired.<br>
<b>Note:</b> Sodium Heparin tubes are acceptable.</p>
<b>Peripheral Blood:</b> 5 mL in EDTA tube.<br>
<b>Note:</b> Test is DNA-based. Please select Extract & Hold - DNA if specimen hold service is desired.<br>
<b>Note:</b> Sodium Heparin tubes are acceptable.</p>
Flag Active
True
Orderable Test Description
This test uses allele-specific PCR on extracted DNA for quantitative detection of the JAK2 V617F mutation, commonly found in myeloproliferative neoplasms (MPN). Test report includes a bar graph to trend the mutational load.
Orderable Turn Around Time
7 Days
Keywords
Orderable Biomarkers
NY Approved
True
Orderable Biomarkers JSON
{"DNA Sequencing": {"SNVs + Indels": ["JAK2"]}}
Keywords string
JAK2 V617F, JAK2 MPN JAK2 V617F Mutation Analysis - Quantitative
Title URL
jak2-v617f-mutation-analysis-quantitative
Clinical Significance
The JAK2 V617F mutation is present in approximately 90% of polycythemia vera (PV) cases and approximately half of primary myelofibrosis (PMF) or essential thrombocythemia (ET). Quantitation of V617F is useful for monitoring MPN patients response to clinical treatment as V617F mutational load correlates with disease course, therefore can be used as a predictive marker.
Storage and transportation
Use cold pack for transport, making sure cold pack is not in direct contact with specimen. Ship same day as drawn whenever possible. Please select extract & hold - DNA if specimen hold service is desired. NYS clients please provide date and time of collection.